December 15, 2006: WILEX
WILEX receives approval for clinical Phase II trial with oral WX-671 in pancreatic cancer

December 13, 2006: WILEX
WILEX receives approval for clinical Phase II trial with oral WX-671 in pancreatic cancer

November 28, 2006: NsGene
NsGeneâ´s proprietary neurotrophic factor, NsG33, will be evaluated by Genzyme for the treatment of motor neuron diseases

November 10, 2006: Smiths Medical, Phasein
SMITHS Medical and Swedish med-tech company PHASEIN sign agreement to market compact capnometer

November 10, 2006: WILEX
WILEX shares successfully placed at EUR 13.80

November 6, 2006: WILEX
Price range for WILEX shares set at EUR 13.80 to EUR 15.80

October 24, 2006: WILEX
WILEX announces details of IPO

October 20, 2006: WILEX
New antibody based diagnostic imaging agent demon-strates 100% positive predictive accuracy in feasibility study

October 16, 2006: WILEX
WILEX successfully completes Phase II study with RENCAREX© in combination with Interferon

October 11, 2006: WILEX
WILEX is specialised in the development of new drugs to fight cancer / IPO is intended to finance the further development of product candidates until regulatory approval

October 6, 2006: Sidec Technologies
Nobel prize winner Roger Kornberg in collaboration with the Karolinska institute and Sidec Technologies AB

September 20, 2006: Cellectricon
Cellectricon receives Swedish governmental R&D grant

August 7, 2006: CWILEX
CWILEX completes Phase I program with anti-cancer drug WX-671 in healthy volunteers and conducts clinical Phase Ib study in cancer patients now

July 31, 2006: WILEX
WILEX completes two Phase Ib studies with anti-cancer drug WXUK1 in cancer patients

May 31, 2006: CanAg Diagnostics
CanAg Diagnostics acquired by Fujirebio Diagnostics

May 16, 2006: Sidec Technologies
Sidec Technologies receives VINNOVA grant

April 19, 2006: Cellectricon
Cellectricon announces record Q1 sales

May 26, 2006: Genizon
Genizon secures $12 million in secured convertible debenture

March 8, 2006: Sidec Technologies, FEI
FEI and Sidec Tackle Validation of Drug Targets

March 1, 2006: WILEX
WILEX Appoints Members to its Medical Advisory Board for Rencarex© and the Phase III ARISER Study

January 12, 2006: Genizon Bioscienses
Genizon Bioscienses converts to Illumina Genotyping technology for disease association research